The company’s proprietary Verisome drug delivery technology is being used as the base for IBI-10090, for post-cataract surgery inflammation. The dexamethasone compound completed a pivotal phase 3 study (n=394), and based on these results, Icon plans to file an NDA by late 2015/early 2016. Phase 3 results builds on the phase 2b data, which showed a 50-60% clearance rate across all doses at Day 8.
Verisome is a “true liquid injection,” that binds the active drug to the carrier and can be administered with standard techniques. The technology allows for drug delivery in as short a duration as 1 week or as long as 9 months. Fully biodegradable, the carrier is eliminated as the drug is dispensed.
Also in the pipeline: A long-acting triamcinolone product that can be delivered with efficacy for up to 12 months. And a latanoprost product is in preclinical studies, with human studies expected to begin in 2015.
David S. Tierney
David S. Tierney, M.D. is President and CEO of Icon Bioscience. Previously, Dr. Tierney was Co-Founder and President of Oceana Therapeutics, sold to Salix Pharmaceuticals in December 2011.